Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.

Jeovanna Lowe,Kyle Floyd,Neha Rastogi,Eric J. Schultz, Jessica A. Chadwick,Sarah A. Swager,Jonathan G. Zins,Feni K. Kadakia,Suzanne Smart,Elise P. Gomez-Sanchez,Celso E. Gomez-Sanchez,Subha V. Raman,Paul M. L. Janssen,Jill A. Rafael-Fortney

Journal of neuromuscular diseases（2016）

引用 13|浏览32

暂无评分

摘要

These data suggest that spironolactone and eplerenone show similar effects in dystrophic mice and support the clinical development of MR antagonists for treating skeletal muscles in Duchenne muscular dystrophy.

查看译文

关键词

Duchenne muscular dystrophy,eplerenone,lisinopril,mineralocorticoid receptors,spironolactone

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要